Prostate cancer screening software Carcinoma.ai©

managementreportingviewer

Since 2019, we have been developing Prostate.Carcinoma.ai© to make PIRADS prostate screening easier, faster and safer. This is what distinguishes our software: Fully automatic 3D segmentation Detection and segmentation of prostate lesions Classification of prostate lesion Supports DICOM standard for data transmission MDR (EU) 2017/745 in 2023 Individual plugin for PACS and Viewer Workstations Prostate.Carcinoma.ai© is available via licensing Artificial intelligence for more efficiency in radiology With an incidence of 1.4 million worldwide, prostate cancer and its detection make up a significant part of a radiologist's workload. With MRI scans of the prostate highly recommended prior to biopsy, capacity must be created to handle the increasing workload. Artificial intelligence (AI) has the potential to take prostate cancer diagnostics to a new level, enabling faster, high-quality, and time-efficient diagnoses. AI and machine learning technologies are facilitating reporting workflows by assisting in the diagnosis, management, and treatment of a wide range of conditions, including prostate cancer, in the shortest possible time. Based on this knowledge, FUSE-AI has developed software that segments the prostate and its zones voxel by voxel and detects suspicious lesions.